Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 88)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
2 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
3 |
|
Cabergoline |
Approved |
Phase 4 |
|
81409-90-7 |
54746 |
Synonyms:
(8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
|
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea
Cabaser
Cabaser®|Caberlin®
Cabaseril
Cabergolina
Cabergoline
Cabergoline diphosphate
Cabergolinum
CABERLIN
Dostinex
FCE-21336
Galastop
|
|
4 |
|
Somatostatin |
Approved, Investigational |
Phase 4 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
5 |
|
Pasireotide |
Approved |
Phase 4 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
6 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
7 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
8 |
|
Octreotide |
Approved, Investigational |
Phase 4 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
9 |
|
Lanreotide |
Approved |
Phase 4 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
10 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
11 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
12 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
13 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
15 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Incretins |
|
Phase 4 |
|
|
|
17 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
18 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
19 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
20 |
|
Protective Agents |
|
Phase 4 |
|
|
|
21 |
|
Hormones |
|
Phase 4 |
|
|
|
22 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
23 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
24 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
25 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
26 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
27 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
28 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
29 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
30 |
|
Sorbitol |
Approved, Investigational |
Phase 3 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
31 |
|
Carboxymethylcellulose Sodium |
|
Phase 3 |
|
|
|
32 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
33 |
|
Tadalafil |
Approved, Investigational |
Phase 2 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
351, IC
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
Adcirca
Adcirca®|Cialis®|IC-351|IC351
Cialis
|
IC351
IC-351
ICOS 351
Tadalafil
Tadalafilo
Tadanafil
Zalutia
|
|
34 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
35 |
|
Clomifene |
Approved, Investigational |
Phase 2 |
|
911-45-5 |
2800 |
Synonyms:
2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine
2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine
2-(p-(b-Chloro-a-phenylstyryl)phenoxy)triethylamine
2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)triethylamine
2-(p-(Β-chloro-α-phenylstyryl)phenoxy)triethylamine
ANDROXAL
Androxal®|Clomid®|clomifene|MER-41|MRL-41|Omifin®|RMI-16289
Chlomaphene
Chloramifene
Chloramiphene
Cisclomiphene
Citrate, clomiphene
Clomid
Clomide
Clomifen
Clomifene
|
Clomifene citrate
Clomifeno
Clomifenum
Clomiphene
Clomiphene citrate
Clomiphene citrate (Z,e)
Clomiphene hydrochloride
Clostilbegit
Dyneric
Gravosan
Hydrochloride, clomiphene
Klostilbegit
Racemic clomiphene citrate
Serophene
Zuclomiphene citrate
|
|
36 |
|
Dimenhydrinate |
Approved |
Phase 2 |
|
523-87-5 |
10660 |
Synonyms:
(O-BENZHYDRYL(DIMETHYLAMINO)ETHANOL) 8-CHLOROTHEOPHYLLINATE
1)
8-CHLORO-1,3-DIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE - 2-(DIPHENYLMETHOXY)-N,N-DIMETHYLETHANAMINE (1
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
ANTEMIN
BENZHYDRYL-BETA-DIMETHYLAMINOETHYLETHER 8-CHLOROTHEOPHYLLINE
Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
BETA-DIMETHYLAMINOETHYL BENZHYDRYL ETHER 1,3-DIMETHYL-8-CHLOROXANTHINE
CHLORANAUTINE
DIMENHIDRINATO
DIMENHYDRINATE
|
DIMENHYDRINATUM
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINATE
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINE
DIPHENHYDRAMINE THEOCLATE
DIPHENHYDRINATE
DRAMAMINE
N,N-DIMETHYL-2-DIPHENYLMETHOXYETHYLAMINE 8-CHLOROTHEOPHYLLINATE
NSC-117855
O-BENZHYDRYLDIMETHYLAMINOETHANOL 8-CHLOROTHEOPHYLLINATE
VERTIGO-VOMEX S
β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
|
|
37 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
38 |
|
Enclomiphene |
Investigational |
Phase 2 |
|
15690-57-0 |
1548953 |
Synonyms:
CISCLOMIPHENE
Enclomifene
Enclomifeno
Enclomifenum
Enclomiphene
ISOMER B
|
MILOPHENE
RMI-16289
SEROPHENE
trans-Clomifene
trans-Clomiphene
|
|
39 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 2 |
|
|
|
41 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
42 |
|
Ethinyl estradiol, levonorgestrel drug combination |
|
Phase 2 |
|
|
|
43 |
|
Mitogens |
|
Phase 2 |
|
|
|
44 |
|
Estrogens |
|
Phase 2 |
|
|
|
45 |
|
Estrogen Receptor Modulators |
|
Phase 2 |
|
|
|
46 |
|
Estrogen Receptor Antagonists |
|
Phase 2 |
|
|
|
47 |
|
Estrogen Antagonists |
|
Phase 2 |
|
|
|
48 |
|
Zuclomiphene |
|
Phase 2 |
|
|
|
49 |
|
Citrate |
|
Phase 2 |
|
|
|
50 |
|
Selective Estrogen Receptor Modulators |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 185)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant |
Unknown status |
NCT02668172 |
Phase 4 |
Pasireotide LAR 60 mg;Pegvisomant |
2 |
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study |
Unknown status |
NCT00552851 |
Phase 4 |
pegvisomant |
3 |
Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range |
Unknown status |
NCT01424241 |
Phase 4 |
Sandostatin LAR |
4 |
Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study |
Unknown status |
NCT02427295 |
Phase 4 |
Sandostatin (Octreotide Acetate) |
5 |
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly |
Completed |
NCT02060383 |
Phase 4 |
Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin |
6 |
Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly |
Completed |
NCT00461149 |
Phase 4 |
Octreotide-LAR |
7 |
Study to Determine Whether Ultrasound Guidance Improves Delivery and Efficacy of Intramuscular Injection of Long-Acting Octreotide in the Treatment of Acromegaly |
Completed |
NCT00552071 |
Phase 4 |
Octreotide LAR 30 MG Injection |
8 |
A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel. |
Completed |
NCT00149188 |
Phase 4 |
Lanreotide (Autogel formulation) |
9 |
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction - A Twelve Month Randomized Cross-Over Study in Patients With Acromegaly |
Completed |
NCT00145405 |
Phase 4 |
Lanreotide Autogel and Octreotide LAR |
10 |
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target |
Completed |
NCT01618513 |
Phase 4 |
Sandostatin® LAR |
11 |
The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment |
Completed |
NCT00595140 |
Phase 4 |
pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline |
12 |
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly |
Completed |
NCT00068042 |
Phase 4 |
Pegvisomant;Sandostatin LAR |
13 |
A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly |
Completed |
NCT00627796 |
Phase 4 |
Lanreotide-Autogel 120 mg |
14 |
A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly |
Completed |
NCT00068029 |
Phase 4 |
Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant |
15 |
A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR |
Completed |
NCT00216398 |
Phase 4 |
Lanreotide (Autogel formulation) |
16 |
Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study |
Completed |
NCT01371643 |
Phase 4 |
Octreotide LAR |
17 |
A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg |
Completed |
NCT00701363 |
Phase 4 |
Lanreotide Autogel 120 mg |
18 |
The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs |
Completed |
NCT00642720 |
Phase 4 |
Pegvisomant |
19 |
Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas |
Completed |
NCT00521300 |
Phase 4 |
Octreotide |
20 |
A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program. |
Completed |
NCT00151437 |
Phase 4 |
Pegvisomant treatment |
21 |
Octreotide Efficacy and Safety in First-line Acromegalic Patients |
Completed |
NCT00171886 |
Phase 4 |
Octreotide |
22 |
A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy |
Completed |
NCT00376064 |
Phase 4 |
Octreotide acetate and cabergoline/Octrotide and Somavert |
23 |
An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen |
Completed |
NCT01278342 |
Phase 4 |
Sandostatin LAR;pegvisomant;cabergoline |
24 |
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment |
Active, not recruiting |
NCT01794793 |
Phase 4 |
Pasireotide;Cabergoline |
25 |
Open Label Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas |
Terminated |
NCT00242541 |
Phase 4 |
Octreotide acetate |
26 |
A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity |
Terminated |
NCT01861717 |
Phase 4 |
lanreotide |
27 |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment |
Unknown status |
NCT03252353 |
Phase 3 |
octreotide capsules;Matching placebo |
28 |
A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands |
Completed |
NCT02685709 |
Phase 3 |
Octreotide capsules |
29 |
Strict IGF-1 Control in Acromegaly (I-Con Study) |
Completed |
NCT02952885 |
Phase 3 |
Pegvisomant |
30 |
A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel |
Completed |
NCT00447499 |
Phase 3 |
Somatuline Autogel (lanreotide acetate) |
31 |
Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly |
Completed |
NCT00499993 |
Phase 3 |
lanreotide (Autogel formulation), duration of treatment 46-48 weeks |
32 |
A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues |
Completed |
NCT02354508 |
Phase 3 |
Pasireotide LAR |
33 |
A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly |
Completed |
NCT00600886 |
Phase 3 |
Pasireotide;Octreotide |
34 |
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly |
Completed |
NCT01137682 |
Phase 3 |
Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg |
35 |
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG - |
Completed |
NCT00143416 |
Phase 3 |
Pegvisomant |
36 |
A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly |
Completed |
NCT02493517 |
Phase 3 |
Lanreotide Autogel®;Lanreotide Acetate |
37 |
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly |
Completed |
NCT00225979 |
Phase 3 |
Octreotide LAR |
38 |
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs |
Completed |
NCT01412424 |
Phase 3 |
Octreotide capsules |
39 |
Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients |
Completed |
NCT00635765 |
Phase 3 |
C2L-OCT-01 PR 30 mg |
40 |
A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR |
Completed |
NCT00444873 |
Phase 3 |
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval |
41 |
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone |
Completed |
NCT00383708 |
Phase 3 |
lanreotide (Autogel formulation);Pegvisomant |
42 |
A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease |
Completed |
NCT00372697 |
Phase 3 |
Octreotide acetate 30 mg suspension |
43 |
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma |
Completed |
NCT00690898 |
Phase 3 |
Lanreotide autogel 120 mg |
44 |
Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients |
Completed |
NCT00128232 |
Phase 3 |
Octreotide LAR |
45 |
Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients |
Completed |
NCT00616551 |
Phase 3 |
C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg |
46 |
Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase. |
Completed |
NCT00234572 |
Phase 2, Phase 3 |
Lanreotide (Autogel formulation) |
47 |
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues. |
Completed |
NCT00210457 |
Phase 3 |
Lanreotide (Autogel formulation) |
48 |
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome |
Completed |
NCT00017927 |
Phase 3 |
Pegvisomant |
49 |
A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly |
Recruiting |
NCT04125836 |
Phase 3 |
CAM2029 (octreotide subcutaneous depot) |
50 |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly |
Recruiting |
NCT04076462 |
Phase 3 |
CAM2029 (octreotide subcutaneous depot);Matching placebo |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
2-Bromoergocryptine Mesylate
Bromocriptine
lanreotide
|
Octreotide
Octreotide Acetate
pegvisomant
|
Cochrane evidence based reviews: acromegaly
|